Croda International Plc (CRDA), the FTSE 100 specialty chemicals group headquartered in the UK, has reported group sales of £449.9m for the third quarter of 2026, representing organic growth of 6.6% against the prior year period. The update, published on 5 November 2026, highlights exceptionally strong performance in Beauty and steady growth in Pharma, while the company confirmed its full-year 2026 outlook remains unchanged. Croda also reiterated it is on track to deliver its transformation plan and financial framework targets for full-year 2028, providing investors with a measure of near-term confidence.

Key Points

  • Croda International Plc (CRDA), FTSE 100 specialty chemicals company founded in 1925 and listed on the London Stock Exchange
  • Group Q3 2026 sales of £449.9m, up 6.6% on an organic basis, driven primarily by Consumer Care
  • Beauty Actives grew 19% organically; Beauty Care grew 13%; Pharma up 5%; Seed Enhancement up 12%; Crop Protection down 9%
  • Investors will be watching whether Q4 2026 seasonal softness and geopolitical uncertainty affect the full-year adjusted operating profit outcome ahead of the 23 February 2027 results announcement

Beauty Actives and Beauty Care Drive Double-Digit Organic Growth in Consumer Care

Consumer Care, Croda's largest division, delivered 10.8% organic sales growth in Q3 2026, with both sales volumes and price/mix positive. Beauty Actives led the segment with 19% organic growth, followed by Beauty Care at 13%, supported by strong demand from global beauty brands for premium and innovation-led ingredients. Home Care contributed 10% organic growth, benefiting from a positive demand environment. Fragrances and Flavours (F&F) posted a more modest 4% organic increase, with performance weighed down by Middle East-related disruption and temporary interruptions to sales in China during a production facility transfer.

Life Sciences Sees Pharma and Seed Enhancement Offset Continued Crop Protection Weakness

Life Sciences delivered 1.8% organic sales growth in Q3 2026, with reported sales sequentially higher than Q2 2026. Pharma sales grew 5% year-on-year, comprising continued progress in Pharma Ingredients for advanced excipients and improved phasing in Pharma Solutions revenues. Seed Enhancement, which operates a services-led model focused on vegetable seeds, delivered 12% organic growth. These gains were partially offset by a 9% organic decline in Crop Protection, which faced a demanding comparison against Q3 2025's 19% constant-currency growth driven by restocking activity. The announcement states that farm income pressure continues to weigh on Crop Protection market demand.

Transformation Programme Targets £100m Annualised Pre-Tax Savings by FY28, with £46m Already Delivered

Croda's ongoing transformation programme is targeting a reduction of approximately £50m in working capital and approximately £100m of total annualised pre-tax benefits, both by full-year 2028. The company disclosed that £46m in cumulative savings had been delivered to 30 June 2026. Additional incremental cost savings are expected in the second half of 2026 and in 2027, with supply chain optimisation cited as a key efficiency driver. The announcement states that Asia was the strongest performing region in Q3 2026, with every business unit delivering organic growth, while Crop Protection weighed on Americas performance.

FY26 Guidance Maintained Despite Geopolitical Uncertainty and Expected Q4 Seasonal Softness

Croda confirmed that its FY26 outlook remains unchanged, with the group continuing to expect organic sales growth within a 3–6% range and a further increase in group adjusted operating margin. Management noted that Q4 2026 absolute sales are expected to be seasonally lower than Q3 2026 at constant currency, as some customers manage working capital into the year end. Foreign currency translation adversely impacted adjusted operating profit by £1.0m in H1 2026, and the company estimates a further negative impact of approximately £4m on reported FY26 operating profit if October 2026 closing exchange rates persist. Full-year 2026 results are scheduled for 23 February 2027.